Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma

AJ Grossberg, LC Chu, CR Deig… - CA: a cancer journal …, 2020 - Wiley Online Library
Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges

JD Martin, H Cabral, T Stylianopoulos… - Nature reviews Clinical …, 2020 - nature.com
Multiple nanotherapeutics have been approved for patients with cancer, but their effects on
survival have been modest and, in some examples, less than those of other approved …

Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment

WL Hwang, KA Jagadeesh, JA Guo, HI Hoffman… - Nature …, 2022 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and treatment-refractory
cancer. Molecular stratification in pancreatic cancer remains rudimentary and does not yet …

Delivery technologies for cancer immunotherapy

RS Riley, CH June, R Langer, MJ Mitchell - Nature reviews Drug …, 2019 - nature.com
Immunotherapy has become a powerful clinical strategy for treating cancer. The number of
immunotherapy drug approvals has been increasing, with numerous treatments in clinical …

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

D Fukumura, J Kloepper, Z Amoozgar… - Nature reviews Clinical …, 2018 - nature.com
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …

Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting

R Rimal, P Desai, R Daware, A Hosseinnejad… - Advanced drug delivery …, 2022 - Elsevier
The tumor microenvironment (TME) is emerging as one of the primary barriers in cancer
therapy. Cancer-associated fibroblasts (CAF) are a common inhabitant of the TME in several …

Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical …

JE Murphy, JY Wo, DP Ryan, JW Clark, W Jiang… - JAMA …, 2019 - jamanetwork.com
Importance Patients with locally advanced pancreatic cancer have historically poor
outcomes. Evaluation of a total neoadjuvant approach is warranted. Objective To evaluate …

Normalizing function of tumor vessels: progress, opportunities, and challenges

JD Martin, G Seano, RK Jain - Annual review of physiology, 2019 - annualreviews.org
Abnormal blood and lymphatic vessels create a hostile tumor microenvironment
characterized by hypoxia, low pH, and elevated interstitial fluid pressure. These …

Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside

T Stylianopoulos, LL Munn, RK Jain - Trends in cancer, 2018 - cell.com
Physical forces have a crucial role in tumor progression and cancer treatment. The
application of principles of engineering and physical sciences to oncology has provided …

Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities

VP Balachandran, GL Beatty, SK Dougan - Gastroenterology, 2019 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest
cancer in the United States by 2025, with 5-year survival at less than 10%. In other …